Publication Name	World Journal of Gastroenterology
Manuscript ID	98783
Country	Taiwan

Received	2024-07-05 07:59
Peer-Review Started	2024-07-05 07:59
To Make the First Decision
Return for Revision	2024-11-10 06:04
Revised	2024-11-18 15:30
Second Decision	2024-12-02 02:38
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-12-02 05:55
Articles in Press	2024-12-02 05:55
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-12-12 07:59
Publish the Manuscript Online	2024-12-20 03:53

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Pharmacology & Pharmacy
Manuscript Type	Letter to the Editor
Article Title	Elafibranor: A promising therapeutic approach for liver fibrosis and gut barrier dysfunction in alcohol-associated liver disease
Manuscript Source	Invited Manuscript
All Author List	Chun-Han Cheng, Wen-Rui Hao and Tzu-Hurng Cheng
ORCID	Author(s) ORCID Number Tzu-Hurng Cheng http://orcid.org/0000-0002-9155-4169
Funding Agency and Grant Number
Corresponding Author	Tzu-Hurng Cheng, PhD, Professor, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, No. 91 Xueshi Road, North District, Taichung 404328, Taiwan. thcheng@mail.cmu.edu.tw
Key Words	Elafibranor; Liver fibrosis; Gut barrier function; Alcohol-associated liver disease; Peroxisome proliferator-activated receptor agonists
Core Tip	This article highlights the major findings of the study written by Koizumi et al. The study demonstrated the potential of elafibranor, a peroxisome proliferator-activated receptor agonist, in mitigating liver fibrosis and improving gut barrier integrity in a mouse model of alcohol-associated liver disease. These findings underscore the promising therapeutic potential of elafibranor and its relevance in advancing treatment strategies for liver diseases linked to chronic alcohol consumption.
Publish Date	2024-12-20 03:53
Citation	<p>Cheng CH, Hao WR, Cheng TH. Elafibranor: A promising therapeutic approach for liver fibrosis and gut barrier dysfunction in alcohol-associated liver disease. <i>World J Gastroenterol</i> 2025; 31(3): 98783</p>
URL	https://www.wjgnet.com/1007-9327/full/v31/i3/98783.htm
DOI	https://dx.doi.org/10.3748/wjg.v31.i3.98783

Full Article (PDF)	WJG-31-98783-with-cover.pdf
Manuscript File	98783_Auto_Edited_013805.docx
Answering Reviewers	98783-answering-reviewers.pdf
Audio Core Tip	98783-audio.mp3
Conflict-of-Interest Disclosure Form	98783-conflict-of-interest-statement.pdf
Copyright License Agreement	98783-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	98783-non-native-speakers.pdf
Peer-review Report	98783-peer-reviews.pdf
Scientific Misconduct Check	98783-scientific-misconduct-check.png
Scientific Editor Work List	98783-scientific-editor-work-list.pdf
CrossCheck Report	98783-crosscheck-report.pdf